Summary
115.47 0.80(0.70%)08/30/2024
Zimmer Biomet Holdings Inc (ZBH)
Zimmer Biomet Holdings Inc (ZBH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.70 | 0.39 | 3.69 | 0.90 | -6.83 | -3.97 | -12.47 | 337.78 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 115.47 | |
| Open | 114.95 | |
| High | 115.93 | |
| Low | 114.63 | |
| Volume | 809,279 | |
| Change | 0.80 | |
| Change % | 0.70 | |
| Avg Volume (20 Days) | 804,189 | |
| Volume/Avg Volume (20 Days) Ratio | 1.01 | |
| 52 Week Range | 102.00 - 133.90 | |
| Price vs 52 Week High | -13.76% | |
| Price vs 52 Week Low | 13.21% | |
| Range | 0.45 | |
| Gap Up/Down | -0.39 | |
Fundamentals | ||
| Market Capitalization (Mln) | 23,514 | |
| EBIDTA | 2,380,100,096 | |
| PE Ratio | 31.4972 | |
| PEG Ratio | 1.9165 | |
| WallStreet Target Price | 167.54 | |
| Book Value | 60.8360 | |
| Earnings Per Share | 3.9140 | |
| EPS Estimate Current Quarter | 1.7600 | |
| EPS Estimate Next Quarter | 2.3400 | |
| EPS Estimate Current Year | 7.4000 | |
| EPS Estimate Next Year | 8.0300 | |
| Diluted EPS (TTM) | 3.9140 | |
| Revenues | ||
| Profit Marging | 0.1039 | |
| Operating Marging (TTM) | 0.1667 | |
| Return on asset (TTM) | 0.0342 | |
| Return on equity (TTM) | 0.0667 | |
| Revenue TTM | 7,883,599,872 | |
| Revenue per share TTM | 37.8520 | |
| Quarterly Revenue Growth (YOY) | -0.0030 | |
| Quarterly Earnings Growth (YOY) | -0.4050 | |
| Gross Profit (TTM) | 4,896,200,000 | |
| Dividends | ||
| Dividend Share | 0.9600 | |
| Dividend Yield | 0.0077 | |
| Valuations | ||
| Trailing PE | 31.4972 | |
| Forward PE | 15.9490 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.0464 | |
| Revenue Enterprise Value | 4.1352 | |
| EBITDA Enterprise Value | 16.0507 | |
| Shares | ||
| Shares Outstanding | 208,908,000 | |
| Shares Float | 208,659,407 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.06 | |
| Institutions (%) | 92.14 | |
08/30 12:30 EST - zacks.com
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
08/21 07:30 EST - prnewswire.com
Zimmer Biomet to Present at the Wells Fargo 2024 and Morgan Stanley Annual Global Healthcare Conferences
WARSAW, Ind. , Aug. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will present at two upcoming healthcare conferences in September.
Zimmer Biomet to Present at the Wells Fargo 2024 and Morgan Stanley Annual Global Healthcare Conferences
WARSAW, Ind. , Aug. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will present at two upcoming healthcare conferences in September.
08/15 10:06 EST - zacks.com
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.
08/08 10:40 EST - zacks.com
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
08/07 13:15 EST - zacks.com
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
08/07 10:36 EST - zacks.com
Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
08/07 08:41 EST - zacks.com
Zimmer Biomet (ZBH) Tops Q2 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.82 per share a year ago.
Zimmer Biomet (ZBH) Tops Q2 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.82 per share a year ago.
08/07 07:45 EST - reuters.com
Zimmer Biomet beats profit estimates on strong demand for medical devices
Zimmer Biomet Holdings beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures.
Zimmer Biomet beats profit estimates on strong demand for medical devices
Zimmer Biomet Holdings beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures.
08/07 06:30 EST - prnewswire.com
Zimmer Biomet Announces Second Quarter 2024 Financial Results
Second quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency1 basis Second quarter diluted earnings per share were $1.18; adjusted1 diluted earnings per share were $2.01 The Company updates 2024 reported revenue guidance due to currency expectations and reaffirms 2024 constant currency revenue growth and adjusted1 earnings per share financial guidance WARSAW, Ind. , Aug. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2024.
Zimmer Biomet Announces Second Quarter 2024 Financial Results
Second quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency1 basis Second quarter diluted earnings per share were $1.18; adjusted1 diluted earnings per share were $2.01 The Company updates 2024 reported revenue guidance due to currency expectations and reaffirms 2024 constant currency revenue growth and adjusted1 earnings per share financial guidance WARSAW, Ind. , Aug. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2024.
08/02 10:21 EST - zacks.com
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Zimmer (ZBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Zimmer (ZBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
07/29 11:00 EST - seekingalpha.com
10 Beaten-Up Blue Chips With Serious Turnaround Potential
Here is my list of blue-chip stocks to research for a buy-on-weakness strategy. Each has the potential to dip by -10% to -20%, given the July S&P 500 correction expands into a more serious bear market. The goal is to purchase stocks at low future PEG Ratios and EV to EBITDA readings for +50% to +100% total returns by the end of 2025.
10 Beaten-Up Blue Chips With Serious Turnaround Potential
Here is my list of blue-chip stocks to research for a buy-on-weakness strategy. Each has the potential to dip by -10% to -20%, given the July S&P 500 correction expands into a more serious bear market. The goal is to purchase stocks at low future PEG Ratios and EV to EBITDA readings for +50% to +100% total returns by the end of 2025.
07/29 07:00 EST - investorplace.com
3 Healthcare Stocks to Buy at a 52-Week Low in July
Finding value in this market is difficult because the S&P 500 has increased over 50% since its bottom in October 2022. Certainly, you won't find it in technology or mega caps, which have soared due to the AI craze.
3 Healthcare Stocks to Buy at a 52-Week Low in July
Finding value in this market is difficult because the S&P 500 has increased over 50% since its bottom in October 2022. Certainly, you won't find it in technology or mega caps, which have soared due to the AI craze.
07/25 11:50 EST - zacks.com
Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.
Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.
07/19 10:41 EST - zacks.com
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
07/17 10:50 EST - zacks.com
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
07/08 07:30 EST - prnewswire.com
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2024 Financial Results
WARSAW, Ind. , July 8, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Wednesday, August 7, 2024 at 8:30 a.m.
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2024 Financial Results
WARSAW, Ind. , July 8, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Wednesday, August 7, 2024 at 8:30 a.m.
07/01 20:46 EST - seekingalpha.com
Zimmer Biomet: Brighter Prospects In H2 2024
Zimmer Biomet's share price has been under pressure in recent months due to soft growth, poor cash flows, and higher interest rates. Demographics, the rise of ASCs and technological advancements should be supportive of long-term growth. Zimmer Biomet also expects new product launches to accelerate growth in the second half of 2024.
Zimmer Biomet: Brighter Prospects In H2 2024
Zimmer Biomet's share price has been under pressure in recent months due to soft growth, poor cash flows, and higher interest rates. Demographics, the rise of ASCs and technological advancements should be supportive of long-term growth. Zimmer Biomet also expects new product launches to accelerate growth in the second half of 2024.
06/21 11:19 EST - benzinga.com
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.
06/20 10:00 EST - zacks.com
3 Generative AI-Based MedTech Stocks to Keep an Eye On
With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.
3 Generative AI-Based MedTech Stocks to Keep an Eye On
With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.
06/20 07:30 EST - prnewswire.com
Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors
WARSAW, Ind. , June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately.
Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors
WARSAW, Ind. , June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately.